linjc16/ctgov huggingface dataset:
The Use of Aromatherapy for Symptom Management

Study Overview
=================
Brief Summary
-----------------
The purpose of this pilot study is to introduce the use of aromatherapy/essential oils to medical oncology patients at Central DuPage Hospital to assess their perceived effectiveness to relieve symptoms of nausea or vomiting and/or anxiety. Peppermint oil will be used for nausea/vomiting and lavender oil will be used for anxiety. This study will involve administration of aromatherapy to a convenience sample of patients, who will then be asked to complete a brief questionnaire. The questionnaire will involve a simple likert scale to measure efficacy (in the opinion of the patient) and simple multiple-choice questions to determine patients' likeliness to use aromatherapy again.

Official Title
-----------------
The Use of Aromatherapy for Symptom Management

Conditions
-----------------
Nausea, Vomiting and Anxiety Associated With Medical Oncology Patients

Intervention / Treatment
-----------------
* Drug: Peppermint and Lavender Essential Oils


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult hospitalized medical oncology patients admitted to Central DuPage Hospital. Age 18 years or greater. Able to understand and speak English. Women of non-childbearing potential or with childbearing potential with a negative pregnancy test documented during the hospital stay. Able to understand concept of aromatherapy for treatment of distressing symptoms. Exclusion Criteria: Prisoners. Non-English speaking patients. Under the age of 18. Unable to comprehend the concept of aromatherapy. Severe cognitive impairment. Not experiencing the symptoms of nausea, vomiting or anxiety. Women with child-bearing potential who have not had a negative pregnancy test during the hospital stay. Patients with known allergy to lavender or peppermint.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Peppermint and Lavender Essential Oils<br> | Drug: Peppermint and Lavender Essential Oils<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post Intervention Patient Interview Form |  | 24hrs post aromatherapy |
Dynamic Arterial Elastance as a Predictor of Arterial Blood Pressure Response to Fluid Administration in Septic Patients

Study Overview
=================
Brief Summary
-----------------
Correction of arterial hypotension is essential for adequate cellular metabolism. maintaining MAP above a minimum level has been recommended in order to prevent further tissue hypoperfusion and organ dysfunction.Functional assessment of arterial load by dynamic arterial elastance (Eadyn), has recently been shown to predict the arterial pressure response to volume expansion (VE) in hypotensive, preload-dependent septic patients.

Detailed Description
-----------------
After approval from the ethics and research committee of Faculty of Medicine, Cairo University, an informed consent will be obtained from each patient's next of kin. Arteial cathter will be inserted in radial artery and connected through an arterial line to invasive arterial blood pressure monitor. Electrical Cardiometry will be attached to patient through the placement of four skin sensors on the neck and left side of the thorax12. A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge (FC).

Official Title
-----------------
Dynamic Arterial Elastance as a Predictor of Arterial Blood Pressure Response to Fluid Administration in Septic Patients

Conditions
-----------------
Sepsis

Intervention / Treatment
-----------------
* Diagnostic Test: fluid challange


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (more than 18 years). Sepsis as a cause of admission. Exclusion Criteria: • Patients younger than 18 years of age. Pregnant females. Trauma as a cause of intensive care unit (ICU)admission. Known medical history of vasodilator therapy. Cardiac arrhythmias. Any absolute contraindication for fluid administration such as congestive heart failure, pulmonary edema and/or fluid overload

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dynamic arterial elastance | confirm the ability of non invasive (Eadyn) for predicting arterial pressure response to fluid challenge in septic patients | 6 month |
Mechanisms of Severe Acute Influenza Consortium (MOSAIC)

Study Overview
=================
Brief Summary
-----------------
The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of Influenza A. By integrating the information that we will gather, we will create a unique overview of how influenza causes illness and what might be done to improve patient management.

Detailed Description
-----------------
Influenza A is one of the best studied viruses, but continues to have a very large impact on human and animal health. In addition to causing outbreaks of winter flu, it sometimes mutates to create a new virus that spreads quickly around the world. It is puzzling that the same virus appears to cause minor or absent symptoms in some people while killing others. Much remains to be understood. The investigators have assembled an unprecedented group of internationally renowned scientists from England and Scotland who will together focus on studying a few hundred people hospitalised during the current swine flu pandemic. Such a large scale project has never before been attempted, but we are now poised to work together and integrate the many recent advances in biomedical science that relate to understanding how influenza causes disease.

Official Title
-----------------
Mechanisms of Severe Acute Influenza Consortium (MOSAIC)

Conditions
-----------------
Influenza

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient admitted to hospital with suspected or confirmed influenza infection Exclusion Criteria: Patients who do not give their consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Influenza diagnosis<br>Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detailed clinical phenotype. Clinicopathological correlation will then be sought between the clinical phenotype and pathological parameters measured as per work packages. |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response to drug treatment and the effect of drug resistance if that emerges. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
severe, acute, influenza, consortium, swine, flu, influenza A, H1N1, hospital, admission
A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

Study Overview
=================
Brief Summary
-----------------
This is a post-marketing, observational, non-interventional, multi-central study of patients with non-small cell lung cancer (NSCLC), with data collected prospectively from medical records at inclusion. The primary objective is to obtain the epidemiologic data of anaplastic lymphoma kinase (ALK)-positive in unselected Chinese patients with NSCLC.

Detailed Description
-----------------
Archived paraffin-embedded and fresh frozen NSCLC tumor tissue will be obtained via the Department of Pathology. ALK positive status will be detected by Ventana immunohistochemistry (IHC) (Ventana Medical Systems, Inc. and Roche Diagnostics International, Inc). When ALK positive patients are detected, crizotinib will be administrated by various solutions based on physician's desecration and patients' willingness. The secondary objectives include: 1.To obtain the epidemiologic data of ALK positive in unselected Chinese patients with NSCLC.2.To describe demographic, socioeconomic [such as age, gender, race/ethnicity, geographic location (including rural/urban area), pathologic parameters, education, family income, National Reimbursement Drug List (NRDL) or Provincial Reimbursement List (PRDL)], and clinical characteristics of NSCLC patients with ALK positive. The exploratory objective is to describe prognosis patterns associated with crizotinib treated patients when efficacy data are available non-interventionally.

Official Title
-----------------
A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China

Conditions
-----------------
Non-small-cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (≥18 years), both sex. Histologically or cytologically proven diagnosis of primary NSCLC, including squamous cell carcinoma and adenocarcinoma. Written informed consent. Exclusion Criteria: Those lung cancers without pathological diagnosis should not be included in case of other types of cancer, including small cell lung cancer (SCLC) or metastatic disease from other organs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the frequency of ALK rearrangement in unselected Chinese patients with non-small cell lung cancer |  | one and half years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| demographic, socioeconomic,clinical and pathological features of ALK-positive NSCLC patients |  | one and half years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-small-cell lung cancer, anaplastic lymphoma kinase, immunohistochemistry
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
CMV is one of the most important opportunistic infection in transplant recipients. In South Korea, more than 95% of adults reveal sero-positivity for CMV IgG. Until now, sero-positivity for CMV IgG before solid organ transplantation is a laboratory test of choice to stratify the risk of CMV reactivation after solid organ transplantation. Theoretically, CMV-specific cell-mediate immune response before solid organ transplantation will further categorize the patients into high or low risk of CMV development after solid organ transplantation. The investigators thus evaluate the usefulness of CMV-specific ELISPOT assay in kidney transplant candidates to predict the development of CMV infection after kidney transplantation.

Detailed Description
-----------------
Between Mar 2014 and Mar 2015, all patients admitted in the kidney transplant unit will be enrolled in this study. All patients will receive CMV-specific ELISPOT assay and be prospectively followed for the development of CMV infection.

Official Title
-----------------
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients (ACE-KT)

Conditions
-----------------
Kidney Transplantation Recipients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 16 or more agree with written informed consent Exclusion Criteria: donor CMV IgG (+) and recipient CMV IgG (-)

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| high CMV ELISPOT results<br>high spot counts in ELISPOT | |
| low CMV ELISPOT results<br>low spot counts in ELISPOT | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CMV infection | CMV infection is defined as follows. CMV viremia: CMV antigenemia or CMV quantitative PCR (+) CMV disease: CMV syndrome or tissue-invasive CMV disease i) CMV syndrome: ① CMV viremia ② temperature > 38 without other cause ③ WBC < 4000, atypical lymphocyte > 3%, transaminase elevation, platelet < 100,000/mm ii) tissue-invasive CMV disease: evidence of CMV in histopathologic specimen (inclusion body or viral antigen in biopsy or bronchoalveolar lavage fluid) | 6 months after transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | 6 months after transplantation | 
| rejection |  | 6 months after transplantation | 
| graft loss |  | 6 months after transplantation |
Partner Notification Intervention for STD Clinics.

Study Overview
=================
Brief Summary
-----------------
To help public health professionals (DIS) in interviews of patients infected with STD for the names of their sex partners, this project used a computer-based partner elicitation program before the actual DIS interview. The main outcome was the mean number of partners named by those who had the intervention versus those those who did not.

Detailed Description
-----------------
The primary goal of this project is to develop and evaluate an intervention that will increase the number of people who, having been exposed to a sexual partner with chlamydia, gonorrhea or syphilis, (a) are notified and (b) receive evaluation and treatment. The intervention program will be presented entirely by an automated multimedia computer system with touch screen interface. The intervention will be tailored to user, based on demographic and recent sexual history factors. The intervention is designed to (a) motivate and prompt STD clinic clients to recall and identify sexual partners, (b) teach clinic clients a set of social skills for minimizing negative reactions while informing partners that they may be infected with an STD; (c) increase client's self-efficacy relative to disclosing partners names and informing them of their STD exposure, and (d) provide clients with tools for motivating their partners to seek treatment.

Official Title
-----------------
Computer-assisted STD Partner Notification

Conditions
-----------------
Contact Tracing

Intervention / Treatment
-----------------
* Behavioral: Computer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 or older AND Anglo, Hispanic, or Black AND STD diagnosis positive Exclusion Criteria: Non-English speaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Computer|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Numbers of partner named. |  |  | 
| 2. Amount and quality of identifying information. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Willingness to name partners. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
video, computer, partner notification
Internet Intervention Promotes Physical Activity in Sedentary Older Adults

Study Overview
=================
Brief Summary
-----------------
This study evaluated the efficacy of a 12-week Internet intervention to help sedentary older adults adopt and maintain an exercise regimen. A total of 368 men and women over 55 years of age (x = 60.3; SD 4.9 ) were recruited and screened on line. They randomized into treatment and control groups and assessed at pre-test, 12 weeks, and at six months. The multivariate model was significant at posttest (p = .001; large effect size) and at six months (p = .001; medium effect size). At posttest, intervention participation showed significant improvement on 13 of 14 outcome measures compared to the control group. At six months, treatment group participants were found to maintain large gains compared to the Ctrl participants on all 14 measures.

Detailed Description
-----------------
Based on the treatment group users self reported fitness level, activity goals, and self-identified barriers to exercise, the program helped users select exercise activities in the areas of endurance, flexibility, strengthening, and balance enhancement. They returned weekly for automated video and text support and education, with the option to change or increase in their exercise plan, and on-going problem solving to overcome barriers to exercise.

Official Title
-----------------
Internet Intervention Promotes Physical Activity

Conditions
-----------------
Exercise, Sedentary Older Adults

Intervention / Treatment
-----------------
* Other: Internet exercise program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 54 years of age; < 61 minutes of exercise per week; internet connection; email address Exclusion Criteria: too young; too active; no web access; no email

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: program visits<br>visits to intervention program | Other: Internet exercise program<br>* 12 voluntary weekly visits to website<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular exercise | Self report: minutes/week | Baseline-6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psycho-social measures (attitudes, knowledge, self efficacy, intentions) | Self rated survey items | Baseline - 6 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physical activity, older adults, Internet, sedentary, multi-week, internet intervention
Evaluation of the Clinical Effectiveness of Naso-alveolar Molding (NAM) Versus Computer Aided Design NAM (CAD/NAM) in Infants With Bilateral Cleft Lip and Palate: A Randomized Clinical Trial

Study Overview
=================
Brief Summary
-----------------
Bilateral cleft lip and palate neonates will be randomly assigned to one of two groups: (gp1 presurgical Naso-alveolar molding (NAM) using Grayson method, gp 2 computer aided design NAM (CAD/NAM). The aim of the study is to compare between short term clinical effects of both interventions as regards alveolar alignment, nasal esthetics and interlabial gap.

Conditions
-----------------
Cleft Lip and Palate

Intervention / Treatment
-----------------
* Device: Naso-alveolar molding (NAM)
* Device: Computer aided design NAM (CAD/NAM)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Bilateral cleft lip and palate Exclusion Criteria: Patients without cleft palate Unilateral cleft lip Patients having systemic medical problems that contraindicate NAM treatment Patients with history of previous presurgical infant orthopedics Patients with history of any surgical procedures (ex: lip adhesion)

Ages Eligible for Study
-----------------
Minimum Age: 7 Days
Maximum Age: 60 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Naso-alveolar molding (NAM)<br>Active plates and nasal stents (Grayson method) | Device: Naso-alveolar molding (NAM)<br> <br> |
| Active Comparator: Computer aided design NAM (CAD/NAM)<br>Computer aided design active plates and nasal stents | Device: Computer aided design NAM (CAD/NAM)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alveolar alignment | Reference points,lines and planes on digital models recording the symmetry and alignment of maxillary arch segments | 5-6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nasal and labial esthetics | Reference points, lines and planes on standardized photos recording the collumellar length, symmetry of nostrils and interlabial gap | 5-6 months |